RFC
TPST icon

Russell Frank Company’s Tempest Therapeutics TPST Stock Holding History

Russell Frank Company’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-14
Closed -$1.16M – 3057
2015
Q2 		$1.16M Buy
+14
New +$1.28M ﹤0.01% 2232
2015
Q1 		– Sell
-8
Closed -$1.04M – 3033
2014
Q4 		$1.04M Buy
+8
New +$586K ﹤0.01% 2119
2013
Q4 		– Hold
0
– – – 3044
2013
Q3 		– Hold
0
– – – 3486

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Russell Frank Company's TPST Position: Q3 2015 in Review

Russell Frank Company sold out of Tempest Therapeutics (TPST) in Q3 2015, closing a stake of 14 shares — an estimated $1.16M sold.

Russell Frank Company first reported a position in TPST in Q4 2014 and held it in 2 quarters. The position peaked at $1.16M in Q2 2015. 90 funds tracked by Wall St. Rank hold TPST as of Q3 2015.

  • Russell Frank Company reported no remaining Tempest Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Russell Frank Company sold 14 Tempest Therapeutics shares in Q3 2015, an estimated $1.16M.
  • Russell Frank Company first reported a position in Tempest Therapeutics in Q4 2014 and held it in 2 quarters.
  • Russell Frank Company's Tempest Therapeutics position peaked at $1.16M in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2015.

Based on Russell Frank Company's 13F filing for Q3 2015, filed 23 Oct 2015.